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Summary
a-Mannosidosis is an autosomal recessive disorder
caused by deficiency of lysosomal a-mannosidase (LA-
MAN). The resulting intracellular accumulation ofman-
nose-containing oligosaccharides leads to mental retar-
dation, hearing impairment, skeletal changes, and
immunodeficiency. Recently, we reported the first a-
mannosidosis–causing mutation affecting two Palesti-
nian siblings. In the present study 21 novel mutations
and four polymorphic amino acid positions were iden-
tified by the screening of 43 patients, from 39 families,
mainly of European origin. Disease-causing mutations
were identified in 72% of the alleles and included eight
splicing, six missense, and three nonsense mutations, as
well as two small insertions and two small deletions. In
addition, Southern blot analysis indicated rearrange-
ments in some alleles. Most mutations were private or
occurred in two or three families, except for a missense
mutation resulting in an R750W substitution. This mu-
tation was found in 13 patients, from different European
countries, and accounted for 21% of the disease alleles.
Although there were clinical variations among the pa-
tients, no significant LAMAN activity could be detected
in any of the fibroblast cultures. In addition, no corre-
lation between the types of mutations and the clinical
manifestations was evident.
Introduction
a-Mannosidosis (MIM 248500) is a rare autosomal re-
cessive disorder caused by deficient activity of lysosomal
a-mannosidase (LAMAN; E.C.3.2.1.24). The major
clinical manifestations of this lysosomal storage disor-
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der are mental retardation, hearing impairment, various
skeletal changes, and recurrent infections. The clinical
variation is considerable, ranging from a severe form
that includes profound mental retardation, hepatosple-
nomegaly, severe dysostosis multiplex, and early death
to a mild form that includes moderate mental retarda-
tion, hearing impairment, milder dysostosis, and survival
into adult life. The diagnosis of a-mannosidosis cur-
rently is based on clinical evaluation, detection of man-
nose-rich oligosaccharides in urine, and direct measure-
ments of a-mannosidase activity in various cell types,
such as leukocytes, fibroblasts, and amniocytes (Chester
et al. 1982; Thomas and Beaudet 1995).
LAMAN is an exoglycosidase that cleaves a-linked
mannose residues as part of the ordered, lysosomal deg-
radation of N-linked oligosaccharides (Aronson and Ku-
randa 1989). The human enzyme is synthesized as a
single-chain precursor that is processed into three main
glycopeptides of 15, 42, and 70 kD (Nilssen et al. 1997).
The gene encoding LAMAN (MANB) has been assigned
to the centromeric region of chromosome 19 (Kaneda
et al. 1987) and consists of 24 exons, spanning 21.5 kb
(GenBank accession numbers U60885–U60899; Riise et
al. 1997). The LAMAN transcript is ∼3,500 nucleotides
(nts) and contains an open reading frame encoding 1,011
amino acids (GenBank U60266; Nilssen et al. 1997).
Thus far, the only humanmutation reported is amissense
mutation resulting in the His72Leu substitution, de-
tected in two Palestinian siblings (HGMD accession
number 119376; Nilssen et al. 1997). a-Mannosidosis
also has been described in cattle (Hocking et al. 1972)
and cats (Burditt et al. 1980). In these animals the as-
sociation of specific mutations to distinct clinical phe-
notypes suggested a correlation between the genotype
and phenotype (Berg et al. 1997a, 1997b; Tollersrud et
al. 1997). Our study was undertaken to identify muta-
tions responsible for a-mannosidosis and to investigate
whether heterogeneity in the LAMAN gene underlies the
clinical variability observed for this disorder.
Patients and Methods
Patients
Patients were diagnosed at the referring center, and
fibroblast cultures, genomic DNA, and blood samples
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were provided by their physicians. Clinical information
was available from 23 of the patients; however, since
patients were evaluated by clinicians from several coun-
tries, clinical data were not collected in a standardized
manner, and proper classification was not possible.
There was no known consanguinity in any of the
families.
DNA and RNA Isolation
Genomic DNA was isolated from skin fibroblasts or
from whole blood, by use of an automated DNA ex-
tractor (341 Nucleic Acid Purification Systems, Applied
Biosystems) or by a salting-out procedure (Miller et al.
1988). RNA was isolated from a 75-cm2 culture flask
of skin fibroblasts or from 1 ml whole blood, by use of
the TRIzol Reagent System (Gibco BRL).
Southern Blot Analysis
Southern blot analysis was performed by use of stan-
dard procedures. Approximately 3–8 mg of genomic
DNA was digested separately with EcoRI and PstI
(Gibco BRL), at 37C overnight, and then was separated
on a 1% agarose gel and transferred overnight to a
GeneScreen Plus membrane (Dupont), by capillary ac-
tion. A 3-kb fragment containing 98% of the LAMAN
coding region was fluorescence labeled by use of the
Gene Images random prime-labelingmodule (Amersham
Life Sciences) and was hybridized to the membrane, at
65C overnight. Bound probe was detected by the Gene
Images CDP-star detection module (Amersham Life Sci-
ences), followed by exposure to BioMax MR film (Ko-
dak) for 5–72 h.
Reverse Transcription (RT) and PCR
Approximately 1 mg total fibroblast or lymphocyte
RNA was reverse transcribed from an oligo-dT primer,
at 45C, by use of the Superscript II kit (Gibco BRL).
Onemicroliter of first-strand cDNA and 0.2 mMof prim-
ers mph5′F-RI and mph3′R-RI (table 1, PCR 1) were set
up in a 25-ml PCR reaction, by use of the TaKaRa LA
PCR kit (TaKaRa Shuzo). PCR conditions were as fol-
lows: 98C for 20 s, 70C for 4 min (7 cycles) and then
98C for 20 s, 66C for 4 min (32 cycles). The PCR
product (3,098 bp), which contained the LAMAN cod-
ing sequence (3,030 bp), was diluted 1:50 in H2O and
was used as a template for nested PCRs (PCRs 2–7).
The LAMAN exons and exon-intron borders were am-
plified from genomic DNA (PCRs 8–21). PCRs 18 and
19 did not give products and were diluted 1:50 prior to
nested PCR (PCRs 18a, 18b, and 19a). For patients for
whom no LAMAN-specific PCR products could be de-
tected after nested PCR, the cDNA quality was evaluated
by RT-PCR of the b-actin gene, using human b-actin–
specific primers (Quick-Screen human cDNA–library
panel, Clontech), or by RT-PCR of the human glyco-
sylasparaginase (GA) gene, using human GA primer B
(Park et al. 1991) in combination with GA reverse exon
5 primer (Nilssen et al. 1993). All amplifications were
performed in a total volume of 25 ml, with 1 ml first-
strand cDNA, 1 ml diluted PCR product or 50–500 ng
genomic DNA, 0.8 mM dNTP, and 0.2 mM each primer,
by use of DynaZyme DNA polymerase (Finnzymes) in
1# DynaZyme buffer. Dimethyl sulfoxide was added to
5% in PCR 8. The PCR conditions were 94C for 60 s
and 66C for 90 s (35 cycles), except for evaluation of
cDNA quality, for which the conditions were 94C for
60 s, 56C for 60 s, and 72C for 60 s.
Nonisotopic RNase-Cleavage Assay (NIRCA)
Prior to NIRCA, the LAMAN coding sequence was
PCR amplified from cDNA, in four overlapping frag-
ments, by use of primers containing the T7 (5′-TAA-
TACGACTCACTATAGGG/A-3′) or SP6 (5′-ATTTAG-
GTGACACTATAGA/GA-3′) promoter sequences added
5′ to the LAMAN-specific sequence (table 1, PCRs 2–5).
NIRCA was performed by use of the MisMatch Detect
II kit (Ambion). Approximately 100 ng PCR product
was transcribed by use of T7 and SP6 RNA polymerases
in 10 ml at 37C for 1 h, in separate tubes, and then 10
ml hybridization buffer was added. Seven microliters of
transcription reactions of opposite polarity was mixed
(patient-T7 to control-SP6, patient-SP6 to control-T7,
and patient-T7 to patient-SP6), boiled for 3 min, and
cooled slowly. A control-T7 to control-SP6 hybridiza-
tion was used as a negative control of cleavage. Five
microliters of hybridized transcript was subjected toRN-
ase cleavage using 15 ml RNase solutions 1, 2, and 3
(diluted 1:100 in RNase digestion buffer), at 37C for
45 min, in separate tubes. The cleavage products were
analyzed on 2.5% agarose gels.
Sequencing and Restriction-Enzyme Analysis
PCR products were treated with exonuclease I and
shrimp alkalic phosphatase, by use of the PCR-product
Presequencing kit (Amersham Life Sciences), and were
directly sequenced from the appropriate primers (see ta-
ble 1 or Nilssen et al. 1997; Riise et al. 1997), by use
of the Thermo Sequenase Radiolabeled Terminator Cy-
cle Sequencing kit (United States Biochemical/Amersham
Life Sciences). When PCR reactions produced multiple
bands, each fragment was gel purified by use of the
Qiaex Gel-Extraction kit (Qiagen) prior to sequencing.
For restriction-enzyme analysis, PCR products were di-
gested overnight with the appropriate enzymes (table 2)
and were analyzed by gel electrophoresis.
Table 1
PCRs
PCR Primer Paira Localization Positionb Sequence (5′r3′)c
Expected Size
(bp)
cDNA:
1 mph5′F-RI Exon 1 23/4 aggacgaattCCCCAGGAGGAAGCTGCTGAGCCATGG 3,101
mph3′R-RI Exon 24 3057–3033 catgcgaattcGGAGGGCCCATCCCAGCAGACCTAA
2 mph1F-T7 Exon 1 10–31 T7-TACGCGCGGGCTTCGGGGGTCT 989
mph7R-SP6 Exon 7 958–941 SP6-AGTCCGAGCCCATGGTCA
3 mph6F-T7 Exon 6 797–815 T7-ATCTGTGCTGGGATGTGCT 1,041
mph14R-SP6 Exon 14 1797–1780 SP6-TCTTCTGGGGATGGGCTG
4 mph14F-T7 Exon 14 1668–1685 T7-CAGCCAGGCGCACCCTCC 649
mph19R-SP6 Exon 18/19 2276–2257 SP6-TAATCCCGCCTCCTCTCCAG
5 mph182F-T7 Exon 18 2229–2242 T7-ACGCTTCTACACAGACAGCA 869
mph3′R-SP6 Exon 24 3051–3042 SP6-CCCATCCCAGCAGACCTAAC
6 mph28F Exon 12 1442–1462 CTCGGCTCAGAGGCTTCAAAG 551
mph306R Exon 16 1992–1972 GGGTCTGAAGATGTAGGCACC
7 mp306F Exon 16 1972–1990 GGTGCCTACATCTTCAGAC 344
mph306bR Exon 19 2315–2295 GCCACGGGCTCCGTCTGGTTC
Genomic DNA:
8 mphf5F-T7 5′ Flank. 372/353 T7-ACGGACACCCTGGATTCCCA 650
mphi1R-SP6 Intron 1 79/62 SP6-CAGACCCACCCACACCTC
9 mphi1F-T7 Intron 1 106/90 T7-CGAGATCAGGCCTCTCT 695
mphi3R-SP6 Intron 3 94/78 SP6-GCTTGCACGTGGCATGA
10 mphi3F-T7 Intron 3 39/20 T7-CTCTGACCGCTGACCCTGAC 321
mphi4R-SP6 Intron 4 47/28 SP6-GCCAGAGTGAGTGAAGAAGT
11 mphi4F-T7 Intron 4 42/23 T7-CTGGGCACTAATTCACACTG 671
mphi6R-SP6 Intron 6 70/50 SP6-TGCCTGTACCATGGAAAGAGC
12 mphi6F-T7 Intron 6 45/27 T7-ATGGCCCAGGATCCTCTGG 264
mphi7R-SP6 Intron 7 62/42 SP6-CCCAAGGCCCCCGGATGCAAG
13 mphi7F-T7 Intron 7 64/43 T7-AGTGTGGGCCCCCAGGAAG 592
mphi10R Intron 10 63/41 CGGCCTAGGGGTGGTTTCCAACT
14 mphi10F-T7 Intron 10 39/18 T7-GAGTCCCACAGAACCTCACTGGAC 221
mphi11R-SP6 Intron 11 33/11 SP6-ACCCCCGTGTCTCCCAAGTCTCG
15 mphi11F-T7 Intron 11 153/133 T7-TATAGTCAAGGGCAGCAGGGT 714
mphi13R-SP6 Intron 13 35/16 SP6-GTCCCAGCGGGGGAATATTC
16 mphi13F-T7 Intron 13 36/16 T7-TACTCTTGACTCAGTTTCCCT 292
mphi14R-SP6 Intron 14 30/10 SP6-GCAGGAAAGGGGATTGAAATG
17 mphi14F-T7 Intron 14 116/97 T7-TGGCTACAGAGTGAGACTCA 500
mphi16R-SP6 Intron 16 43/21 SP6-CTTCCCCATTCCCAACTGCCCA
18 mphi162F-T7 Intron 16 30/9 T7-CTTACACCCACCTCACCCGTTGT 456
mphi18R Intron 18 95/71 GTCTCCCAAACTCATGTAATCAGCA
18a mphi162F-T7 Intron 16 30/9 T7-CTTACACCCACCTCACCCGTTGT 343
mp3R Exon 18 2249–2227 CGGCCATTGCTGTCAGTGTAGAA
18b mph3.5F Exon 17 2095–2114 CAGGTGGTTCGCCTGTACCC 357
mphi18R Intron 18 95/71 GTCTCCCAAACTCATGTAATCAGCA
19 mph3F Exon 18 2229–2249 CTACACAGACAGCAATGGCCG ∼1,750
mph2R Exon 21 2535–2513 CAGCACCAGGTGGCGCCCTCGCA
19a mphi18F-T7 Intron 18 93/73 T7-TGACAGAGCGAGACTCCATC 457
mphi202R-SP6 Intron 20 31/10 SP6-CTGGCCTCGGATGGGGCTCTGA
20 mphi20F-T7 Intron 20 49/30 T7-CACCCACAAACCCACGACTC 357
mphi21R-SP6 Intron 21 40/19 SP6-CTTCAATCCGGTCCTCTCTGCC
21 mphi21F-T7 Intron 21 42/24 T7-CCCCGCCCCTCTCCAACTC 4,833
mphi23R-SP6 Intron 23 35/16 SP6-CTCCACCCCTTCCCTACCCC
22 mphi23F-T7 Intron 23 72/54 T7-GAGGAAGCATCGTGGGGTG 435
mphf3′R-SP6 3′ Flank. 109/90 SP6-TTACAGGAGCAAGCCACCAC
a mph primers were designed from the human cDNA sequences (Nebes and Schmidt 1994; Nilssen et al. 1997), mp primers from the bovine
cDNA sequence (Tollersrud et al. 1997), and mphi and mphf primers from the human genomic sequence (Riise et al. 1997). RI  EcoRI site
added to the 5′ end of the primer. F  forward, and R  reverse.
b Position 1 refers to A in the first in-frame ATG (codon 1) in the cDNA sequence reported by Nilssen et al. (1997), but, in all patients and
normal controls studied, an insertion of GCC (encoding Ala) was detected between nts 6 and 7. Since deletion of this GCC appears to be a
rare polymorphism, we have changed the numbering of the cDNA and protein to include the insertion. For primer mph5′F-RI and for the intron
and flanking primers, positive values indicate positions downstream of the previous exon, and negative values indicate positions upstream of
the preceeding exon.
c Lowercase letters indicate 5′ overhangs containing EcoRI sites. Mismatches to the human cDNA sequence (Nilssen et al. 1997) or the
genomic DNA sequence (Riise et al. 1997) are underlined.
Table 2
Detection of Mutations and Polymorphisms in the LAMAN Gene
Designation(s) PCR Primers (Size [in bp])a
Method of
Detectionb Expected Size of Bands (in bp)
Mutation(s):
H72L mphi1F/mphi3R (657) RE, MslI Normal: 18216012811968
Mutant: 27918212868
W77X mphi1F-T7/mph30R (574) RE, HinfI Normal: 731410126
Mutant: 731160250126
IVS5-1GrC mphi5F/mph262R (212) RE, PstI Normal: 12191
Mutant: 212
965delAT mphi6F-T7/mphi7R-SP6 (264) Sequencing )
IVS72TrG mphi6F-T7/mphi7R-SP6 (264) RE, BsmBIc Normal: 17094
Mutant: 264
T355P mphi7F-T7/mphi10R (592) Sequencing )
P356R mphi7F-T7/mphi10R (592) RE, HhaI Normal: 3467946121
Mutant: 1242227946121
1076–1077insA mphi7F-T7/mphi10R (592) RE, HpaI Normal: 592
Mutant: 130463
Y359X mphi7F-T7/mphi10R (592) RE, HpaI Normal: 592
Mutant: 130462
1153–1154insCC mph26bF/mph27R (98) PAGE Normal: 98
Mutant: 100
E402K mphi7F-T7/mphi10R (592) Sequencing )
IVS11-3del25 mphi11F-T7/mphi12R-SP6 (409) AGE Normal: 409
Mutant: 384
IVS122TrG mphi11F-T7/mphi12R-SP6 (409) Sequencing )
E563X mphi13F/mphi14R (370) RE, MspI Normal: 156214
Mutant: 370
1815delA mphi13F/mphi14R (370) RE, MseI Normal: 28585
Mutant: 369
IVS141GrC mphi13F/mphi14R (370) RE, DdeI Normal: 21694436200
Mutant: 2169443613367
IVS14-2ArG mphi14F-T7/mph306R (382) RE, MspI Normal: 134248
Mutant: 1259248
W714R mph3.5F/mphi18R (357) RE, BsrBI Normal: 358
Mutant: 45312
IVS171GrA,
IVS171GrT
mphi16F/mphi182R (573) RE, HphI Normal: 245233156198110
Mutant: 245233354110
R750W mph3.5F/mphi18R (357) RE, HaeIII Normal: 571847046
Mutant: 5725446
L809P mph306bF/mphi202R-SP6 (317) RE, MspI Normal: 46271
Mutant: 4620962
Polymorphism:
L/V278 mphi5F/mph262R (212) RE, MspI L278: 59153
V278: 5912924
T/I312 mphi6F-T7/mphi7R-SP6 (264) RE, TspRIc T312: 939675
I312: 18975
R/Q337 mphi6F-T7/mphi7R-SP6 (264) RE, MspI R337: 68966733
Q337: 6816333
N/S413 mph26bF/mphi10R (335) RE, BbvI N413: 153182
S413: 15357125
IVS1034A/C mph26bF/mphi10R (335) RE, AciIc IVS1034A: 22205108
IVS1034C: 222057830
IVS1863G/A mphi16F/mphi182R (573) RE, HphI IVS1863G: 245233156198110
IVS1863A: 2452331561985159
a PCR conditions were 95C for 1 min, 64C for 1 min, and 72C for 1 min (for 35 cycles). Primer sequences are listed in table 1, in
the report by Nilssen et al. (1997), or in the report by Riise et al. (1997), except for primers mphi12R-SP6 (SP6-CTTCGCAGCCCA-
CGTAATTTCACT, position 108/85 in intron 12), mphi16F (AATTATGTGGCGGTGACTGAAGGT, position 134/111 in intron
16), and mphi182R (GGCTCCCCCGCCCTTCACTCT, position 109/129 in intron 18). F  forward, and R  reverse.
b RE  restriction-enzyme digestion, and AGE  agarose-gel electrophoresis.
c Sequencing was performed because of ambiguous results after restriction-enzyme digestion.
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Immunoprecipitation
Polyclonal antiserum was obtained by immunization
of male Chinchilla rabbits with native human placenta
LAMAN (Nilssen et al. 1997) and was IgG enriched by
use of standard protocols. Fibroblasts from one 75-cm2
culture flask were lysed in PBS containing 1% Triton-
X100, incubated at 4C for 1 h, and centrifuged. The
supernatant was assayed for a-mannosidase activity, in
0.1 M sodium acetate, pH 4.5, and 4 mM 4-methylum-
belliferyl a-D-mannopyranoside (Sigma), at room tem-
perature for 2–7 h. The enzyme activity was correlated
to the total amount of protein in the sample, which
was measured by the DC-protein assay kit (Bio-Rad).
LAMAN was immunoprecipitated from the superna-
tant, by use of standard protocols, and the immunopre-
cipitate was assayed for a-mannosidase activity. The en-
zyme activity was correlated to the amount of protein
prior to immunoprecipitation. All assays were per-
formed in duplicate.
Results
Outline of Strategy for Mutation Analysis
By screening for the mutation resulting in the H72L
substitution, described by Nilssen et al. (1997), we ex-
cluded this mutation in the 43 patients. Southern blot
analysis using LAMAN cDNA as a probe was performed
to search for large gene aberrations. Extra bands were
observed in five patients. RNA and cDNAwere prepared
from the 32 patients from whom fresh blood or fibro-
blasts were available, and the LAMAN coding region
was PCR amplified in four overlapping fragments. RT-
PCR products were obtained from 24 of these patients.
Of the eight patients who failed to give LAMAN RT-
PCR products, four expressed normal levels of b-actin
and GA mRNA, as determined from agarose-gel elec-
trophoresis of RT-PCR products, indicating lack of LA-
MAN mRNA production. The remaining four patients
showed no or very low amounts of control RT-PCR
products, indicating that the quality of the cDNA was
poor. LAMAN RT-PCR products of reduced sizes were
observed in six patients. These fragments were directly
sequenced, and the underlying splicing mutations were
determined from genomic DNA. Fragments of sizes in-
distinguishable from the control fragments were sub-
jected to mutation analysis using enzymatic cleavage of
mismatched heteroduplexes (NIRCA). RT-PCRproducts
corresponding to the cleaved fragments were sequenced,
and the mutations also were verified by sequencing of
genomic DNA. For some of the patients with at least
one unidentified mutation after the cDNA analysis (pa-
tients 10, 14, 16, and 30) or from whom cDNA was
not available (patients 2, 5, and 22), all 24 exons and
the exon-intron borders were PCR amplified from ge-
nomic DNA and directly sequenced. Using this com-
bined strategy, we identified 16 new mutations. All
patients were screened for these mutations, by restric-
tion-enzyme analysis or DNA sequencing. Five addi-
tional mutations were found during this screening. The
21 mutations (tables 3 and 4 and fig. 1) were present in
36 of the 43 patients (table 5). Genomic DNAwas avail-
able from the family members of 12 patients (5, 7, 13,
14, 15A, 15B, 19, 20A, 20B, 21A, 21B, and 22), and,
in these families, the parents were found to carry the
mutations.
LAMAN Mutations
The mutations detected in this study are listed in tables
3 and 4. Splicing mutations (table 3) were predicted
when the RT-PCR analysis revealed lack of an entire
exon or parts of an exon. The cryptic exonic splice sites
that were activated conformed to the consensus GT-AG
rule (Padgett et al. 1986), except for the site activated
as a result of IVS5-1GrC, in which case the activated
acceptor site in exon 6 was TG, not the consensus AG
dinucleotide. Nonconsensus splice sites are rare and usu-
ally are involved in alternative splicing (Jackson 1991).
The IVS72TrG mutation resulted in the production
of two different transcripts, devoid of 9 and 12 nts. A
cryptic GT donor site at position 1015 in exon 7 was
used for both transcripts. There were no genomic se-
quence alterations in the intron 7 acceptor site in this
patient, and the inclusion of an extra codon in the largest
transcript appeared to result from use of an alternative
acceptor site 3 nts upstream of the commonly used site
of intron 7. Splicing heterogeneity is also supported by
the presence of this extra codon at the same position in
the cDNA sequence reported by Nebes and Schmidt
(1994). The alternative splicing is probably a rare event,
since the codon was absent from all control cDNAs
tested.
In addition, IVS11-3del25 resulted in the production
of two types of transcripts, the largest of which was a
result of activation of a cryptic acceptor site in exon 12.
Agarose-gel electrophoresis of RT-PCR products cov-
ering exon 12 showed that this transcript was less abun-
dant than the transcript that lacked the entire exon.
IVS171GrA and IVS171GrT also resulted in pro-
duction of two types of transcripts. As determined from
gel electrophoresis, these transcripts were present in
equal amounts.
We identified six new missense mutations (table 4).
None of the 140 Norwegian control alleles contained
the T355P, P356R, E402K, W714R, or R750W substi-
tutions, whereas the L809P replacement was found on
1 of 196 Norwegian normal alleles. The T355P, P356R,
E402K, andW714R variants were private. Themutation
leading to R750W was detected on 4 of 12 Finnish dis-
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Table 3
Splice Mutations in the LAMAN Gene
Mutation Designation Sequence Alteration Effect on Transcript Effect on Protein
IVS5-1GrC AGrAC in acceptor
site of intron 5
Deletion of the first 15 nts of exon 6
(764–778)
Deletion of Val256–Gly260
IVS72TrG GTrGG in donor site
of intron 7
(I) Deletion of the last 12 nts of
exon 7 (1015–1026);
(II) Deletion of the last 12 nts of
exon 7 (1015–1026) plus inclusion
of 3 nts of intron 7
(I) Deletion of Val339–Gln342;
(II) Deletion of Val339–Ala341
IVS11-3del25 Deletion of 25 bp pre-
ceeding 2 in accep-
tor site of intron 11
(I) Deletion of exon 12 (1420–1527);
(II) Deletion of the first 66 nts of
exon 12 (1420–1485)
(I) Deletion of Val474–Arg509;
(II) Deletion of Val474–Gln495
IVS122TrG GTrGG in donor site
of intron 12
Deletion of exon 12 (1420–1527) Deletion of Val474–Arg509
IVS141GrC GTrCT in donor site
of intron 14
Deletion of exon 14 (1645–1830) Deletion of Val549–Glu610
IVS14-2ArG AGrGG in acceptor
site of intron 14
Deletion of the first 31 nts of exon
15 (1831–1861)
Frameshift after Glu610, termi-
nation at codon 612
IVS171GrA GTrAT in donor site
of intron 17
(I) Deletion of exon 17 (2047–2165);
(II) Deletion of the last 24 nts of
exon 17 (2142–2165)
(I) Frameshift after Lys682, ter-
mination at codon 694;
(II) Trp714Cys plus deletion of
Ser715–Gly722
IVS171GrT GTrTT in donor site
of intron 17
Same as for IVS171GrA Same as for IVS171GrA
NOTE.—We have used the mutation nomenclature suggested by Antonarakis (1998). For an explanation of the numbering of
nucleotides and codons, see footnote b in table 1. “(I)” and “(II)” refer to alternative forms of transcripts resulting from the same
splicing mutation.
ease alleles but was excluded as a polymorphism in
Finns, by the screening of 80 control alleles from this
population. The same mutation was found on five of
eight Polish disease alleles, as well as in single cases orig-
inating from Germany, Italy, Sweden, The Netherlands,
and Turkey. Also, a cell line deposited in the National
Institute of General Medical Sciences (NIGMS) cell re-
pository contained this mutation, but information con-
cerning the patient’s country of origin was not available.
In total, the R750W variant was present on 18 (21%)
of the 86 disease alleles. The L809P substitution was
present on one Norwegian and three Swedish alleles.
Southern blot analysis revealed the presence of extra
bands in five patients (1, 3, 8, 14, and 25), when com-
pared with 80 control alleles. Patients 1 and 25 showed
abnormal restriction patterns for both EcoRI and PstI.
Patients 3, 8, and 14 showed abnormal patterns only
for one enzyme (EcoRI or PstI). Patient 14 was hetero-
zygous for a mutation that disrupted a PstI site (IVS5-
1GrC), which probably explains the abnormal restric-
tion pattern. The molecular basis of the other abnormal
bands was not determined.
Six allelic variants were identified in this study (table
4). T/I312 and R/Q337 have been described elsewhere
(Nilssen et al. 1997; Riise et al. 1997). The two intronic
polymorphisms did not seem to affect the splicing
process. These six variants were classified as polymor-
phisms not associated with a-mannosidosis, since they
were present in homozygous states in several controls.
LAMAN Activity in a-Mannosidosis Fibroblasts
a-Mannosidase activity was assayed in fibroblasts
from 22 of the patients and was found to be 5%–10%
of the activity in controls (data not shown). However,
since other a-mannosidases, such as Golgi a-mannosi-
dase II (Moremen and Robbins 1991), also are active at
a low pH, the specific LAMAN activity was determined
after immunoprecipitation with antibodies against hu-
man placenta LAMAN. In all patients, the level of cross-
reacting a-mannosidase activity was !1.3% of that in
controls (not shown), but there was no consistent var-
iation between the patients.
Clinical Classification of Patients
Clinical classification was based on symptoms de-
scribed by Chester et al. (1982). There was considerable
variation in the severity of skeletal abnormalities and
mental retardation. One patient (17) with a splicing mu-
tation died at 26 mo of age from respiratory failure and
may represent the most severe form of a-mannosidosis
(Aylsworth et al. 1976; Patton et al. 1982; Thomas and
Beaudet 1995). Other patients (1, 6, 12–16, 18–22,
24–28, 31, and 32) were less severely affected, but their
symptoms still were not as mild as those of the patients
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Table 4
Mutations and Polymorphisms in the LAMAN Gene
Mutation Designation Sequence Alteration Effect on Coding Sequence
Missense:
H72La ArT at 215 in exon 2 His72Leu susbstitution
T355P ArC at 1063 in exon 8 Thr355Pro susbstitution
P356R CrG at 1067 in exon 8 Pro356Arg substitution
E402K GrA at 1204 in exon 9 Glu402Lys substitution
W714R TrC at 2140 in exon 17 Trp714Arg substitution
R750W CrT at 2248 in exon 18 Arg750Trp substitution
L809P TrC at 2426 in exon 20 Leu809Pro substitution
Insertion or deletion:
1076–1077insA Insertion of A between 1076 and 1077 in exon 8 Direct termination at codon 359
1153–1154insCC Insertion of CC between 1153 and 1154 in exon 9 Frameshift after Pro384, termination at codon 476
965delAT Deletion of AT at 965–966 in exon 7 Direct termination at codon 322
1815delA Deletion of A at 1815 in exon 14 Frameshift after Leu605, termination at codon 623
Nonsense:
W77X GrA at 231 in exon 2 Termination at codon 77
Y359X CrA at 1077 in exon 8 Termination at codon 359
E563X GrT at 1687 in exon 14 Termination at codon 563
Polymorphism:
L/V278 C or G at 832 in exon 6 Leu or Val at codon 278
T/I312a C or T at 935 in exon 7 Thr or Ile at codon 312
R/Q337a G or A at 1010 in exon 7 Arg or Gln at codon 337
N/S413 A or G at 1238 in exon 10 Asn or Ser at codon 413
IVS1034A/C A or C at 34 in intron 10 No effect
IVS1863G/A G or A at 63 in intron 18 No effect
NOTE.—We have used the mutation nomenclature suggested by Antonarakis (1998). For an explanation of the numbering of nu-
cleotides and codons, see footnote b in table 1.
a Reported previously by Nilssen et al. (1997) and Riise et al. (1997).
reported by Warner et al. (1984) and Bennet et al.
(1995). Moderate clinical manifestations in the majority
of the patients was consistent with a previous study
based on 160 cases (Chester et al. 1982).
Discussion
This study presents the first spectrum of mutations in
a-mannosidosis. Twenty-one new mutations were char-
acterized and included eight splicing mutations, six mis-
sense mutations, three nonsense mutations, two small
insertions, and two small deletions (tables 3 and 4 and
fig. 1). Putative disease-causing mutations were identi-
fied on 62 (72%) of the 86 disease alleles studied. In
addition, four exonic and two intronic nonpathogenic
polymorphisms were identified.
Technical Aspects of the Mutation Detection
cDNA analyses, involving agarose-gel electrophore-
sis and NIRCA, revealed mutations only on 16 alleles
from the 24 patients (33%) who were shown to express
LAMAN mRNA. One explanation for this low degree
of detection is that cDNA analysis does not detect mu-
tations that reduce the production or stability of mRNA.
This was probably the case for seven patients (1, 3,
6, 10, 11, 13, and 17) who, by comparison of the
cDNA and genomic sequences, were found to express
mRNA from one allele only. Notably, six of the muta-
tions (IVS72TrG [leading to the deletion of 12 nts
from the transcript], 1063ArC, 1204GrA, 1238ArG,
2248CrT, and 2426TrC) identified by sequencing of
genomic DNA were not detected by NIRCA, although
sequencing later showed that these mutations were pres-
ent in the cDNA. This demonstrates the limited sensi-
tivity of this method of mutation detection. The cDNA
analyses were also complicated by the presence of al-
ternatively spliced transcripts for which no underlying
mutations could be detected. The aberrant transcript
that occurred most frequently contained intron 13 and
lacked exon 8 and thus was identical to a transcript
reported by Liao et al. (1996) that did not encode a
functional LAMAN.
Seven patients were analyzed by the sequencing of all
exons and exon-intron borders. Mutations were iden-
tified in all these patients, except for the mutation on
the paternal allele of patient 14. RT-PCR showed that
this patient expressed only the maternal allele carrying
the IVS5-1GrC mutation, which disrupts a PstI site.
Southern blot analysis revealed the presence of an ad-
ditional band after PstI digestion. This pattern also was
present in the mother and is probably a result of the
IVS5-1GrC mutation. It is possible that the mutation
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Figure 1 Localization of the mutations and polymorphisms in the LAMAN gene. Exons are represented by boxes; blackened areas indi-
cate UTRs.
on the paternal allele is outside the analyzed regions or
that unidentified intronic polymorphisms lead to allele-
specific amplification of the maternal allele. Abnormal
restriction patterns also were seen in patients 1, 3, and
25, in whom only one of the mutations had been found
by the screening of genomic DNA. These patients also
showed the normal bands, indicating heterozygosity for
the mutation causing the abnormal restriction pattern.
Additional bands also were present in patient 8, who
appeared to be homozygous for a 2-bp deletion in exon
7. Determination of the molecular basis for these ab-
normal bands is in progress. Eighteen patients appeared
to be homozygous for specific mutations, but DNA was
available only from the parents of 6 of these patients.
We therefore cannot exclude the possibility that the 12
remaining patients (2, 4, 8, 9, 18, 23, 27, 28, and 30–33)
carry additional mutations causing allele-specific ampli-
fication or genomic rearrangements not detectable by
Southern blot analysis.
Characteristics of the Mutations
The deletions, insertions, and nonsense mutations all
resulted in premature termination of translation, which
indicates that these mutations were pathogenic. The
splicing mutations were probably also disease causing,
even though the reading frame remained intact in
some of the misspliced transcripts. Six sequence variants
(L/V278, T/I312, R/Q337, N/S413, IVS1034A/C, and
IVS1863G/A) were found in homozygous states in nor-
mal controls, proving that these polymorphisms do not
cause a-mannosidosis. In contrast, the mutations leading
to T355P, P356R, E402K, W714R, and R750W were
not found on 140 control alleles, whereas 1 of 196 con-
trol alleles carried the mutation leading to the L809P
substitution. The absence or very low frequency of car-
riers in a normal population does not prove that these
six missense mutations are disease causing, but several
observations indicate that they are pathogenic. First,
T355P, R750W, and L809P were identified in patients
for whom all exons and exon-intron borders were se-
quenced, which indicates that there were no other dis-
ease-causing mutations on these alleles. Second, all six
amino acid substitutions resulted in profound changes
in the side-chain properties of the affected residues.
Third, T355 is conserved among all class 2 a-mannosi-
dases, whereas the five other amino acid residues are
conserved among the four mammalian LAMANs cloned
to date (i.e., human [Nilssen et al. 1997], cattle [Tol-
lersrud et al. 1997], cat [Berg et al. 1997b], and mouse
[Beccari et al. 1997]). E402K was found on the same
allele as the splicing mutation IVS72TrG. The splicing
mutation probably has a more profound effect on the
gene product than does the E402K substitution, since
the splicing mutation leads to deletion of three or four
amino acids. Expression studies are required, to deter-
mine which of these two mutations causes loss of activ-
ity. It also is possible that both mutations are required
for inactivation of the gene product.
The high degree of mutational heterogeneity of a-
mannosidosis, with 22 mutations identified thus far, is
comparable to that of many other genetic disorders. Six-
teen of the 33 unrelated patients included in this study
appeared to be homozygous. This indicates that a-man-
nosidosis often is associated with consanguinity, al-
though we could not confirm this in any of the families.
Most mutations were private, but seven mutations oc-
curred in more than one family. The 1153–1154insCC
and IVS14-2ArG mutations were found in two Nor-
wegian families, whereas Y359X and IVS17GrT were
present in two German and two Italian families, re-
spectively. Both IVS141GrC and L809P were present
in three families each, all originating from northern Eu-
rope. The mutation leading to R750W was found in
patients from several countries and accounted for 21%
of the disease alleles. Haplotype analysis is required, to
address whether the mutations occurring in more than
one family are identical by descent or are recurrent mu-
tations. Unfortunately, we were unable to perform a
proper haplotype analysis, since we lackedDNA samples
from the family members of many patients. By testing
the five R750W homozygotes (patients 5, 18, 23, 31,
and 33) for the L/V278, R/Q337, N/S413, IVS1034A/
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Table 5
Mutations in a-Mannosidosis Patients
Patient Ethnicity Mutation on Allele 1 Mutation on Allele 2 Source(s)
1a Dutch W77X ND O. P. van Diggelen, Rotterdam
2a,b Dutch 1076–1077insA 1076–1077insA R. Wevers, Nijmegen, The Netherlands;
Jansen et al. (1987)
3a,b Dutch R750W ND O. P. van Diggelen, Rotterdam
4a Finnish IVS141GrC IVS141GrC M. Renlund, Helsinki
5a Finnish R750Wc R750Wc M. Renlund, Helsinki
6a,b Finnish R750W ND GM00654;d Autio et al. (1973)
7a Finnish R750Wc ND M. Renlund, Helsinki
8a French (Re´union) 935delAT 935delAT E. Vamos, Brussels; Farriaux et al. (1975)
9a,b French (Re´union) IVS171GrA IVS171GrA C. Largillie`re, Lille, France; Farriaux et al.
(1975)
10a,b German Y359X IVS11-3del25 M. Beck, Mainz, Germany
11a,b German Y359X IVS72TrG, E402K M. Beck, Mainz, Germany; Spranger et al.
(1976)
12b German 1815delA IVS141GrC M. Beck, Mainz, Germany; Gehler et al.
(1975)
13 German R750Wc ND M. Beck, Mainz, Germany
14a,b Greek IVS5-1GrCc ND H. Michelakakis, Athens
15A Italian IVS122TrGc IVS122TrGc R. Gitzelmann and N. U. Bosshard, Zurich
15B Italian IVS122TrGc IVS122 TrGc R. Gitzelmann and N. U. Bosshard, Zurich
16 Italian T355P IVS171GrT R. Gatti, Genoa
17a Italian IVS171GrT ND R. Gatti, Genoa; Cerruti Mainardi et al.
(1982)
18a Italian R750W R750W B. Bertagnolio, Milan
19a,b Norwegian 1153–1154insCCc 1153–1154insCCc D. Malm and L. Tranebjærg, Tromsø,
Norway; Malm et al. (1995)
20Aa,b Norwegian 1153–1154insCCc IVS14-2ArGc D. Malm and L. Tranebjærg, Tromsø,
Norway; Malm et al. (1995)
20Bb Norwegian 1153–1154insCCc IVS14-2ArGc D. Malm and L. Tranebjærg, Tromsø,
Norway; Malm et al. (1995)
21Ab Norwegian IVS14-2ArGc IVS14-2ArGc D. Malm and L. Tranebjærg, Tromsø,
Norway
21Bb Norwegian IVS14-2ArGc IVS14-2ArGc D. Malm and L. Tranebjærg, Tromsø,
Norway
22a Norwegian IVS141GrCc L809Pc D. Malm and L. Tranebjærg, Tromsø,
Norway
23a,b Polish R750W R750W O. P. van Diggelen, Rotterdam
24a,b Polish R750W ND B. Czartoryska, Warsaw
25a Polish R750W ND B. Czartoryska, Warsaw
26a Polish R750W ND B. Czartoryska, Warsaw
27a,b Spanish W714R W714R E. Vamos, Brussels; Loeb et al. (1969)
28b Spanish E563X E563X A. Chaba`s and M. J. Coll, Barcelona
29b Swedish R750W L809P J.-E. Ma˚nsson, Mølndal, Sweden
30a,b Swedish L809P L809P J.-E. Ma˚nsson, Mølndal, Sweden
31a,b Turkish R750W R750W O. P. van Diggelen and J. G. N. de Jong,
Rotterdam; Jansen et al. (1987)
32a,b Caucasian P356R P356R GM04518d
33a,b Caucasian R750W R750W GM02817d
NOTE.—ND  not determined. In the patient designations, “A” and “B” indicate that the the patients are siblings.
a Southern blot analysis performed; underlining indicates that abnormal results were obtained.
b LAMAN activity determined.
c Parents analyzed.
d Deposited in the NIGMS Human Genetic Mutant Cell Repository.
C, and IVS1863G/A polymorphisms, we found that
750W appeared on two different haplotypes. The Finn-
ish, Italian, and Polish homozygotes, as well as the
GM02817 cell line, shared the same haplotype (L278,
R337, S413, IVS1034C, and IVS1863G), whereas
the Turkish patient differed at one position (N413). The
presence of 750W on two different haplotype back-
grounds suggests that there may have been two inde-
pendent mutational events. This is supported by the dis-
persed geographic distribution of the mutation and by
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its location in a CpG dinucleotide, which is a hot spot
for mutations (Cooper and Youssoufian 1988).
Relationship between the Mutations and the
Biochemical and Clinical Features
The LAMAN activity in immunoprecipitates from pa-
tient fibroblasts was !1.3% of normal. Because of fluc-
tuations among parallel samples, we were unable to ob-
tain precise values for the enzyme activity in individual
patients. However, the range of values (0.3%–1.3%) re-
mained constant, which indicates that residual activities
were below the detection limit of the method. The results
from previous studies show both absence (Burditt et al.
1978; Pohlmann et al. 1983) and presence (Mersmann
and Buddecke 1977; Poenaru et al. 1980) of crossre-
acting activities in patients. This could reflect different
mutations resulting in different levels of residual LA-
MAN activity. Alternatively, these variations could be
due to differences in the specificity of the antibodies
(Thomas and Beaudet 1995). Bach et al. (1978) sug-
gested that the relatively mild phenotype of two Pales-
tinian siblings was due to a high level of residual
a-mannosidase activity, as measured by cellogel electro-
phoresis followed by an enzyme assay. However, we
could not detect any significant crossreacting a-man-
nosidase activity even in these patients.
Except for an Italian patient (17) who had died at age
2 years, all patients presented moderate clinical features.
Two siblings (patients 21A and 21B) presented with rel-
atively mild mental retardation and skeletal changes, and
one of them is still, at age 32 years, employed at a “shel-
tered workplace.” These siblings were homozygous for
a frameshift splicing mutation that most likely abolished
LAMAN activity. The more severely affected patient (17)
was heterozygous for a splicing mutation. Although the
mutation on the other allele remained unidentified for
this patient, our results indicate that no specific class of
mutations is associated withmoderately ormore severely
affected patients. Since no patients with mild phenotypes
were available for this study, we cannot exclude the pos-
sibility that particular mutations are restricted to such
patients.
Clinical variation within sibships has been reported
for a-mannosidosis (Mitchell et al. 1981; Michelakakis
et al. 1992), as well as for related disorders such as
fucosidosis (Thomas and Beaudet 1995). Both environ-
mental and other genetic factors may contribute to var-
iations in clinical expression. Since a-mannosidosis pa-
tients, especially those at a young age, suffer from
recurrent infections, environmental factors may contrib-
ute to severe infections that lead to early death and thus,
by definition, presentation of a “severe” clinical picture.
Other a-mannosidases may contribute to salvage path-
ways for the degradation of glycoproteins. Indeed, the
pattern of oligosaccharides in the urine of a-mannosi-
dosis patients indicates that at least partial degradation
of a-mannosidic linkages occurs in the absence of LA-
MAN (Chester et al. 1982; Warner et al. 1984; Mich-
alski 1996). Interestingly, strong evidence of a role for
cytosolic a-mannosidase in the intracellular degradation
of oligosaccharides was provided recently (Grard et al.
1996). It therefore is possible that allelic heterogeneity
of this or other extra-lysosomal a-mannosidases could
influence the clinical expression of a-mannosidosis.
However, Warner et al. (1984) observed similar patterns
and levels of mannose-containing oligosaccharides in the
urine of a very mildly affected and two more severely
affected patients, which indicates that factors other
than a-mannosidase activity contribute to the clinical
heterogeneity.
In conclusion, we found considerable mutational het-
erogeneity in a-mannosidosis, with a higher prevalence
of certain mutations in some restricted geographic lo-
cations. Our study forms the basis of DNA-based diag-
nostics for a-mannosidosis. However, such diagnostic
studies cannot be used to predict clinical expression,
since environmental and epigenetic factors appear to be
the main causes for the clinical variation observed in a-
mannosidosis.
Note added in proof.—Recently, Gotodo et al. (1998)
reported mutations in five a-mannosidosis patients, in-
cluding P355R in one patient and R750W in two pa-
tients. These three patients are identical to patients 32,
6, and 33, respectively, in our study (see table 5). Gotodo
et al. also identified a nonsense mutation (Q639X) in
the patient corresponding to patient 6 in our study, while
their patient with the H72L substitution is identical to
the Palestinian patient reported by Nilssen et al. (1997).
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